Streetbeat News

Products Services

NYAX

Nayax Ltd. (Nasdaq: NYAX) is launching its suite of attended retail payment solutions in 40 new European markets, targeting retailers and hospitality businesses.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

RLMD

Relmada Therapeutics announced that the Phase 3 Reliance II trial for their CNS drug is deemed futile by the Data Monitoring Committee, indicating it is unlikely to meet its primary efficacy endpoint. Despite this setback, Relmada will focus on developing REL-P11 for metabolic disease and has $54.1 million in cash reserves.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

AWI

Armstrong World Industries (NYSE: AWI) has acquired A. Zahner Company, enhancing its capabilities in exterior architectural metal solutions. Zahner is known for its advanced metal surfaces and engineering systems.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

HRMY

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) for potential violations of federal securities laws. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

ROCK

Gibraltar Industries, Inc. (Nasdaq: ROCK) will present at the BofA Clean Energy Symposium on December 6, 2024. The company's CEO and CFO will meet with investors, highlighting its role in the residential, renewable energy, agtech, and infrastructure markets.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

PSTV

Plus Therapeutics will present interim data from its Phase 1 trial of Rhenium (186Re) Obisbemeda for treating leptomeningeal metastases in breast cancer patients at the 2024 San Antonio Breast Cancer Symposium.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

ARVN

PFE

Levi & Korsinsky has initiated an investigation into Arvinas, Inc. for potential federal securities law violations. Arvinas and Pfizer have delayed the completion of their Phase 3 trial for a breast cancer therapy, impacting investor confidence.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

AMLX

Amylyx Pharmaceuticals has announced the design of its pivotal Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist, aimed at treating post-bariatric hypoglycemia. The trial will focus on reducing hypoglycemia events.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

CRM

Salesforce shares surged 12.5% in premarket trading following the company's announcement of better-than-expected quarterly sales and a positive outlook for its new AI-integrated products.

Portfolio Pulse from

December 04, 2024 | 12:30 pm

PTF

The article discusses the Invesco Dorsey Wright Technology Momentum ETF (PTF), which provides broad exposure to the Technology sector. It is a passively managed ETF launched on October 12, 2006.

Portfolio Pulse from

December 04, 2024 | 12:30 pm